Treatment Response Modeling
1 Time Course of Improvement
Treatment responses in ME/CFS are characteristically slow, with meaningful improvement often requiring weeks to months. The model explains this through the timescales of parameter recovery:
- Fast (hours to days): Direct pharmacological effects—e.g., symptom relief from analgesics, blood pressure support from fludrocortisone, heart rate reduction from beta-blockers. These modify \(J_\text{demand}\) or compensatory variables without addressing underlying dysfunction.
- Medium (weeks to months): Repair of accumulated damage—mitochondrial biogenesis (\(\tau ~ 2\)–$ 4$ weeks), immune system remodeling (\(\tau ~ 4\)–$ 8$ weeks), neuroplastic changes (\(\tau ~ 6\)–$ 12$ weeks). These modify the damage variable \(D_\text{total}\), gradually improving system capacity.
- Slow (months to years): Epigenetic reprogramming, immune cell lineage reconstitution (after B cell depletion, new naive B cells repopulate over 6–12 months (Fluge et al. 2011)), and neuroendocrine axis resetting.
The model predicts that treatments targeting fast timescale effects (symptom management) provide immediate but limited benefit, while treatments targeting medium and slow timescale processes (disease modification) show delayed onset but potentially greater magnitude of improvement.
2 Combination Therapy Effects
The integrated model enables simulation of multi-target interventions. Combination therapy can produce synergistic effects when interventions target complementary pathways. For example, the model predicts that combining CoQ10 (increasing ETC capacity) with an anti-inflammatory agent (reducing \(J_\text{immune}\)) produces greater ATP surplus than either alone, because the energy freed from reduced immune demand is processed more efficiently through the enhanced ETC. Formally, synergy occurs when:
\[ \Delta [\text{ATP}]_{\text{A+B}} > \Delta [\text{ATP}]_\text{A} + \Delta [\text{ATP}]_\text{B} \tag{1}\]
The model identifies the parameter combinations most likely to produce synergy, providing a rational basis for combination therapy design rather than empirical trial-and-error.